This focus on DCs is particularly relevant given cDC1s’ established role in orchestrating effective anti-tumor immune responses and immunotherapy outcomes, as T cells checkpoint inhibition alone proves insufficient without cDC1-mediated antigen presentation to expand tumor-specific CD8+ T cells populations. The gene discussed is CD8A; the disease is neoplasm.